Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Taro gets co-development rights to NovaBiotics' Novexatin

Executive Summary

Taro Pharmaceutical Industries Ltd.’s Taro Pharmaceuticals North America Inc. has licensed exclusive US co-development and marketing rights to NovaBiotics Ltd.’s (antibacterial and antifungal therapeutics) Phase IIb-ready Novexatin (NP213 peptide) for mild-to-moderate onychomycosis.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
      • Topical Delivery
Deal Status
  • Final
Deal Type
  • Alliance
    • R&D and Marketing (Licensing)

Related Companies